Drugs / Adenovirus-p53 transduced dendritic cell vaccine
Adenovirus-p53 transduced dendritic cell vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT01302821 Background | Jan 2013 → Dec 2014 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenovirus-p53 transduced dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302821 ↗ |
| Modality | Vaccine | “The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites.” NCT01302821 ↗ |